1
|
Tarrasón G, Carcasona C, Eichhorn P, Pérez B, Gavaldà A, Godessart N. Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system. Exp Dermatol 2017; 26:1105-1111. [DOI: 10.1111/exd.13392] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/06/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Gema Tarrasón
- Skin Biology and Pharmacology; Almirall R&D Center; Sant Feliu de Llobregat Barcelona Spain
| | - Carla Carcasona
- Skin Biology and Pharmacology; Almirall R&D Center; Sant Feliu de Llobregat Barcelona Spain
| | - Peter Eichhorn
- Pharmacokinetics and Metabolism; Almirall R&D Center; Sant Feliu de Llobregat Barcelona Spain
| | - Bibiana Pérez
- Pharmacokinetics and Metabolism; Almirall R&D Center; Sant Feliu de Llobregat Barcelona Spain
| | - Amadeu Gavaldà
- Skin Biology and Pharmacology; Almirall R&D Center; Sant Feliu de Llobregat Barcelona Spain
| | - Núria Godessart
- Skin Biology and Pharmacology; Almirall R&D Center; Sant Feliu de Llobregat Barcelona Spain
| |
Collapse
|
2
|
Devillier P, Garrigue E, D'Auzers G, Monjotin N, Similowski T, Clerc T. V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Respir Res 2015; 16:68. [PMID: 26050967 PMCID: PMC4462001 DOI: 10.1186/s12931-015-0227-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 05/29/2015] [Indexed: 01/08/2023] Open
Abstract
Background Long acting bronchodilators are the standard of care in the management of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the efficacy and safety of V0162, a novel anticholinergic agent with bronchodilator properties, in preclinical models and in patients with COPD. Methods Guinea pigs were used to evaluate the impact of V0162 on the acetylcholine or histamine-induced bronchoconstriction. V0162 was also investigated in an allergic asthma model on ovalbumin-sensitized guinea pig. For clinical investigations, healthy volunteers were included in a dose-escalation, randomized, placebo-controlled phase I study to determine the maximal tolerated dose, followed by a randomized, placebo-controlled, cross-over phase II study in patients with COPD. V0162 was given via inhalation route. The objectives of the phase I/II study were to assess the safety and efficacy of V0162, in terms of bronchodilation and reduction in hyperinflation. Results Preclinical results showed that V0162 was able to prevent bronchoconstriction induced either by acetylcholine or histamine. V0162 reversed the bronchoconstriction and airway inflammation caused by ovalbumin challenge in sensitized guinea pigs. In the healthy volunteers study, 88 subjects were enrolled: 66 received V0162 and 22 received placebo. No particular safety concerns were raised. The maximal tolerated dose was not reached and the dose escalation was stopped at 2400 μg. A total of 20 patients with COPD were then enrolled. All patients received a single-dose of V0162 1600 μg and of placebo in two alternating periods. In COPD patients, V0162 demonstrated a significant increase in FEV1 compared with placebo (148 ± 137 ml vs. 36 ± 151 ml, p = 0.003). This bronchodilatory effect was corroborated by a reduction in hyperinflation. There was a trend toward dyspnea relief (change in visual analog scale at 22 h, −15.1 ± 26.0 mm vs.- 5.3 ± 28.8 mm with placebo, p = 0.054). No serious adverse events (AEs) were reported. Most common AEs were productive and non-productive cough, dyspnea and pruritus. Conclusions V0162 improved pulmonary function and tended to improve dyspnea in patients with COPD over more than 24 h. The slight plasmatic exposure observed might support the good safety profile. Trial registration ClinicalTrials.gov identifier: NCT01348555
Collapse
Affiliation(s)
- Philippe Devillier
- UPRES EA 220, Hôpital Foch, Université de Versailles Saint Quentin, 11 rue Guillaume Lenoir, Suresnes, 92150, France.
| | - Eric Garrigue
- Centre de Recherche et de Développement Pierre Fabre Toulouse, 3 Avenue Hubert Curien BP 13562, 31035, Toulouse, France.
| | - Guillaume D'Auzers
- Centre de Recherche et de Développement Pierre Fabre Toulouse, 3 Avenue Hubert Curien BP 13562, 31035, Toulouse, France.
| | - Nicolas Monjotin
- Institut de Recherche Pierre Fabre, Service de Pharmacologie, CEPC Bel Air de Campans, Castres Cedex, 81106, France.
| | - Thomas Similowski
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale (Département "R3S"), 47-83 Bd de l'Hôpital, F-75013, Paris, France. .,Sorbonne Universités, UPMC Paris 06, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", F-75005, Paris, France. .,INSERM, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", F-75005, Paris, France.
| | - Thierry Clerc
- Centre de Recherche et de Développement Pierre Fabre Toulouse, 3 Avenue Hubert Curien BP 13562, 31035, Toulouse, France.
| |
Collapse
|
3
|
Sawaguchi M, Tanaka S, Nakatani Y, Harada Y, Mukai K, Matsunaga Y, Ishiwata K, Oboki K, Kambayashi T, Watanabe N, Karasuyama H, Nakae S, Inoue H, Kubo M. Role of Mast Cells and Basophils in IgE Responses and in Allergic Airway Hyperresponsiveness. THE JOURNAL OF IMMUNOLOGY 2012; 188:1809-18. [DOI: 10.4049/jimmunol.1101746] [Citation(s) in RCA: 128] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
4
|
Dunford PJ, Holgate ST. The role of histamine in asthma. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2011; 709:53-66. [PMID: 21618887 DOI: 10.1007/978-1-4419-8056-4_6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Histamine is a ubiquitous inflammatory mediator intimately associated with the pathology of allergy. Traditional antihistamines, targeting the histamine H1 receptor, have failed to demonstrate a significant role for histamine in asthma. Novel immunomodulatory roles for histamine and the discovery of a novel histamine receptor, the histamine H4 receptor, have resulted in a reassessment of its importance in asthma.
Collapse
Affiliation(s)
- Paul J Dunford
- Department of Immunology, Johnson & Johnson Pharmaceutical Research & Development, LLC, San Diego, California 92121, USA.
| | | |
Collapse
|
5
|
Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008; 7:41-53. [PMID: 18172439 DOI: 10.1038/nrd2465] [Citation(s) in RCA: 385] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Histamine has a key role in allergic inflammatory conditions. The inflammatory responses resulting from the liberation of histamine have long been thought to be mediated by the histamine H1 receptor, and H1-receptor antagonists--commonly known as antihistamines--have been used to treat allergies for many years. However, the importance of histamine in the pathology of conditions such as asthma and chronic pruritus may have been underestimated. Here, we review accumulating evidence suggesting that histamine indeed has roles in inflammation and immune function modulation in such diseases. In particular, the discovery of a fourth histamine receptor (H4) and its expression on numerous immune and inflammatory cells has prompted a re-evaluation of the actions of histamine, suggesting a new potential for H4-receptor antagonists and a possible synergy between H1 and H4-receptor antagonists in targeting various inflammatory conditions.
Collapse
Affiliation(s)
- Robin L Thurmond
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. San Diego, California 92121, USA.
| | | | | |
Collapse
|
6
|
Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y. A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor. Eur J Pharmacol 2007; 563:224-32. [PMID: 17336292 DOI: 10.1016/j.ejphar.2007.01.074] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2006] [Revised: 01/19/2007] [Accepted: 01/24/2007] [Indexed: 11/17/2022]
Abstract
Eosinophilic chemokines and histamine play distinct but important roles in allergic diseases. Inhibition of both eosinophilic chemokines and histamine, therefore, is an ideal strategy for the treatment of allergic inflammation, such as asthma, allergic rhinitis, and atopic dermatitis. YM-344484 was found to potently inhibit both the CCL11-induced Ca2+ influx in human CCR3-expressing cells (Kb=1.8 nM) and histamine-induced Ca2+ influx in histamine H1 receptor-expressing PC3 cells (Kb=47 nM). YM-344484 also inhibited the CCL11-induced chemotaxis of human CCR3-expressing cells (IC50=6.2 nM) and CCL11-induced eosinophil-derived neurotoxin release from human eosinophils (IC50=19 nM). Orally administered YM-344484 inhibited the increase in histamine-induced vascular permeability in mice (82% inhibition at a dose of 10 mg/kg) and the accumulation of eosinophils in a mouse asthma model (74% at a dose of 300 mg/kg). These results indicate that YM-344484, a novel and functional dual antagonist for chemokine CCR3 receptor and histamine H1 receptor, is an attractive candidate for development as a novel anti-allergic inflammation drug.
Collapse
MESH Headings
- Animals
- Anti-Allergic Agents/pharmacology
- Anti-Allergic Agents/therapeutic use
- Anti-Inflammatory Agents/pharmacology
- Anti-Inflammatory Agents/therapeutic use
- Asthma/chemically induced
- Asthma/complications
- Calcium Signaling/drug effects
- Capillary Permeability/drug effects
- Cell Line, Tumor
- Chemotaxis/drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Eosinophil-Derived Neurotoxin/metabolism
- Eosinophils/drug effects
- Eosinophils/metabolism
- Female
- Histamine/pharmacology
- Histamine Antagonists/pharmacology
- Histamine Antagonists/therapeutic use
- Humans
- Mice
- Mice, Inbred BALB C
- Ovalbumin
- Piperidines/pharmacology
- Pneumonia/etiology
- Pneumonia/prevention & control
- Pulmonary Eosinophilia/etiology
- Pulmonary Eosinophilia/prevention & control
- Pyridazines/pharmacology
- Rats
- Receptors, CCR3
- Receptors, Chemokine/antagonists & inhibitors
- Receptors, Chemokine/genetics
- Receptors, Chemokine/metabolism
- Receptors, Histamine H1/drug effects
- Receptors, Histamine H1/metabolism
- Skin/blood supply
- Transfection
Collapse
Affiliation(s)
- Keiko Suzuki
- Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Osaka 532-8514, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
DuBuske LM. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother 2006; 6:2511-23. [PMID: 16259582 DOI: 10.1517/14656566.6.14.2511] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist. It relieves the symptoms of seasonal allergic rhinitis (including nasal obstruction and congestion, and morning symptoms), perennial allergic rhinitis and chronic idiopathic urticaria by blocking multiple critical steps in the systemic allergic cascade and downregulating key allergy-induced inflammatory mediators. It also relieves asthma symptoms and decreases rescue medication use in patients with seasonal allergic rhinitis and comorbid asthma. Numerous clinical studies have demonstrated that desloratadine is safe, well tolerated and free of serious cardiac effects. Pharmacokinetic studies have demonstrated a low propensity for drug-drug or drug-food interactions. This review outlines the mechanism of action, efficacy and safety of desloratadine for the treatment of allergic inflammatory disorders.
Collapse
MESH Headings
- Adult
- Aged
- Animals
- Anti-Inflammatory Agents/administration & dosage
- Anti-Inflammatory Agents/pharmacokinetics
- Anti-Inflammatory Agents/therapeutic use
- Asthma/drug therapy
- Child
- Child, Preschool
- Chronic Disease
- Clinical Trials, Phase III as Topic
- Drug Administration Schedule
- Histamine H1 Antagonists, Non-Sedating/administration & dosage
- Histamine H1 Antagonists, Non-Sedating/pharmacokinetics
- Histamine H1 Antagonists, Non-Sedating/therapeutic use
- Humans
- Infant
- Loratadine/administration & dosage
- Loratadine/analogs & derivatives
- Loratadine/pharmacokinetics
- Loratadine/therapeutic use
- Product Surveillance, Postmarketing
- Randomized Controlled Trials as Topic
- Rhinitis, Allergic, Perennial/drug therapy
- Rhinitis, Allergic, Seasonal/drug therapy
- Urticaria/drug therapy
Collapse
|
8
|
Bryce PJ, Mathias CB, Harrison KL, Watanabe T, Geha RS, Oettgen HC. The H1 histamine receptor regulates allergic lung responses. J Clin Invest 2006; 116:1624-32. [PMID: 16680192 PMCID: PMC1448167 DOI: 10.1172/jci26150] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2005] [Accepted: 03/07/2006] [Indexed: 01/16/2023] Open
Abstract
Histamine, signaling via the type 1 receptor (H1R), has been shown to suppress Th2 cytokine production by in vitro cultured T cells. We examined the role of H1R in allergic inflammation in vivo using a murine asthma model. Allergen-stimulated splenic T cells from sensitized H1R-/- mice exhibited enhanced Th2 cytokine production. Despite this Th2 bias, allergen-challenged H1R-/- mice exhibited diminished lung Th2 cytokine mRNA levels, airway inflammation, goblet cell metaplasia, and airway hyperresponsiveness (AHR). Restoration of pulmonary Th2 cytokines in H1R-/- mice by intranasal IL-4 or IL-13 restored inflammatory lung responses and AHR. Further investigation revealed that histamine acts as a T cell chemotactic factor and defective T cell trafficking was responsible for the absence of lung inflammation. Cultured T cells migrated in response to histamine in vitro, but this was ablated by blockade of H1R but not H2R. In vivo, allergen-specific WT but not H1R-/- CD4+ T cells were recruited to the lungs of naive recipients following inhaled allergen challenge. H1R-/- T cells failed to confer airway inflammation or AHR observed after transfer of WT T cells. Our data establish a role for histamine and H1R in promoting the migration of Th2 cells into sites of allergen exposure.
Collapse
Affiliation(s)
- Paul J Bryce
- Division of Immunology, Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
| | | | | | | | | | | |
Collapse
|
9
|
Schwarze J, Hamelmann E, Gelfand EW. Barometric whole body plethysmography in mice. J Appl Physiol (1985) 2005; 98:1955-7; author reply 1956-7. [PMID: 15829724 DOI: 10.1152/japplphysiol.01279.2004] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
There has been significant utilization of the technique described by Hamelmann et al. ( Am J Respir Crit Care Med 156: 766–775, 1997) in which a parameter, enhanced pause (Penh), related to airways responsiveness is noninvasively measured by unrestrained plethysmography (UP). Investigating this technique, we sought to answer these questions: 1) How do changes in Penh compare with changes in traditional plethysmographic and lung mechanical parameters? 2) How do UP parameters perform in two different mouse strains? Awake immunized and control BALB/c ( n = 16) and C57BL/6 ( n = 14) mice were placed in the UP chamber and exposed to doses of aerosolized methacholine while the following parameters were measured at each concentration: inspiratory time (Ti), expiratory time (Te), total time (Ttot), Ti/Ttot, peak inspiratory pressure, peak expiratory pressure, Pause, Penh, tidal volume (Vt), Vt/Ti, Vt/Te, and Vt/Ttot. The next day, lung resistance (Rl) and compliance (Cl) were invasively measured in the same animals. For the BALB/c, the parameters with the highest magnitude of correlation coefficient vs. Rl are (in order) 1) Cl, 2) Pause and Penh, 3) parameters of breathing frequency (Te, Ttot, Ti), and 4) parameters related to Vt (inspiratory pressure, expiratory pressure). Flow parameters (Vt/Ttot, Vt/Te, Vt/Ti) and duty cycle parameters (Ti/Ttot) had insignificant correlations. This ordering is significantly different in C57BL/6 mice, in which the parameters with the largest correlations are 1) Cl, 2) parameters of breathing frequency, and 3) flow parameters. Pause, Penh, Vt, and duty cycle parameters had insignificant correlations. These data show that Penh is problematic in the sense that it is strain specific; it behaves very differently in BALB/c and C57BL/6 mice. We suggest that UP parameters largely originate as part of reflex control of breathing processes, rather than in the lung mechanics and conclude that it is inappropriate to use UP parameters in general, and Penh specifically, as substitute variables for invasive mechanical indexes such as Rl.
Collapse
|